LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Inicio・Lista de Acciones・Fate Therapeutics Inc

Fate Therapeutics Inc

Cerrado

SectorSalud

1.05 3.96

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

1.11

Métricas clave
By Trading Economics
Ingresos	-4.5M -52M
Ventas	-1.2M 1.9M
BPA	-0.44
Margen de beneficio	-2,803.925
Empleados	181
EBITDA	10M -42M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+409.9% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 ago 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	5.3M 123M
Apertura anterior	-2.91
Cierre anterior	1.05

Noticias sobre sentimiento de mercado

By Acuity

74%

26%

354 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

0.9101 / 1.14 Soporte y Resistencia

Fate Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 may 2025, 22:52 UTC

Ganancias

Principales Movimientos del Mercado

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 may 2025, 20:37 UTC

Principales Noticias

Ganancias

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 may 2025, 00:00 UTC

Charlas de Mercado

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 may 2025, 23:47 UTC

Charlas de Mercado

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 may 2025, 23:38 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 may 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 may 2025, 23:14 UTC

Principales Noticias

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 may 2025, 22:46 UTC

Principales Noticias

Adquisiciones, fusiones, absorciones

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 may 2025, 21:58 UTC

Ganancias

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 may 2025, 21:24 UTC

Ganancias

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 may 2025, 20:56 UTC

Charlas de Mercado

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 may 2025, 20:54 UTC

Charlas de Mercado

Ganancias

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 may 2025, 20:54 UTC

Ganancias

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 may 2025, 20:51 UTC

Ganancias

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 may 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 may 2025, 20:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 may 2025, 20:50 UTC

Ganancias

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 may 2025, 20:26 UTC

Principales Noticias

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 may 2025, 20:25 UTC

Ganancias

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparación entre iguales

Cambio de precio

Fate Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

409.9% repunte

Estimación a 12 meses

Media 5.15 USD 409.9%

Máximo 12 USD

Mínimo 2 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Fate Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

Comprar

Mantener

Vender

De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para Fate Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.9101 / 1.14Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentimiento

By Acuity

354 / 382 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.